Targeting a specific protein to treat certain lung cancers
Targeting SMARCA2 as a therapeutic strategy in SMARCA4 mutant lung cancer
['FUNDING_R01'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-10897013
This study is exploring a new treatment for lung cancer patients with a specific genetic change, focusing on a molecule called YD23 that may help kill cancer cells by targeting a protein important for their survival.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10897013 on ClinicalTrials.gov |
What this research studies
This research investigates a new treatment approach for lung cancer patients with specific genetic mutations. It focuses on the SMARCA2 protein, which has been found to be crucial for the survival of lung cancer cells that have mutations in the SMARCA4 gene. Using advanced techniques, the researchers have developed a novel molecule, YD23, that selectively degrades SMARCA2, potentially leading to the death of these cancer cells. The study aims to provide preclinical evidence to support the future use of YD23 in treating patients with SMARCA4 mutant lung cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have mutations in the SMARCA4 gene.
Not a fit: Patients without SMARCA4 mutations or those with other types of lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new targeted therapy for patients with specific mutations in lung cancer, improving treatment options and outcomes.
How similar studies have performed: Other research has shown promise in targeting similar pathways in cancer treatment, indicating that this approach could be effective.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LISSANU, YONATHAN — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: LISSANU, YONATHAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.